Cargando…
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study
In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial...
Ejemplares similares
-
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset
por: Langer, Thorsten, et al.
Publicado: (2020) -
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study
por: Clemens, Eva, et al.
Publicado: (2019) -
Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study
por: Seesing, M F J, et al.
Publicado: (2019) -
Economic evaluation of endometrial scratching before the second IVF/ICSI treatment: a cost-effectiveness analysis of a randomized controlled trial (SCRaTCH trial)
por: van Hoogenhuijze, N E, et al.
Publicado: (2021) -
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)